ArticleBlood2017
Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia.
Open access · bronzeAbstract readMulticenter Study
In one paragraph
Article in Blood, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 191 papers.
0numbers the graph read from it
0cells of the map it votes in
191citing papers in PubMed
30.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
191 citing papers in PubMed, 403 citations in OpenAlex.
- Trial
- Trial
- New method of FACS analyzing and sorting of intact whole ovarian fragments (COPAS) after long time (24 h) cooling to 5 °C before cryopreservation.Cell and tissue banking · 2021Trial
- Trial
- Next-generation sequencing indicates false-positive MRD results and better predicts prognosis after SCT in patients with childhood ALL.Bone marrow transplantation · 2017Trial
- Measurable Residual Disease.Methods in molecular biology (Clifton, N.J.) · 2027Article
- AI In Leukemia Diagnostics: Complementing the Pathologist's Role.International journal of laboratory hematology · 2026Review
- Strategies to Overcome Inequities in the Treatment of Patients with Hematologic Malignancies.Current hematologic malignancy reports · 2026Review
- A genomic and epigenomic lens into the biology of acute lymphoblastic leukaemia.Nature reviews. Cancer · 2026Review
- Dimensionality reduction enables MRD visualization in single-sample flow cytometric analysis in acute leukemia.International journal of hematology · 2026Article
- Article
- Review
- Article
- Optimizing limited antibody panels for efficient hematological disorders diagnosis by flow cytometry in resource-constrained setting.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Observational
- Low flow cytometry events in detecting CNS involvement in pediatric B-cell precursor ALL: NGS validation and prognostic significance.Blood advances · 2026Article
- Next-Generation Sequencing for Minimal Residual Disease Detection in Pediatric Acute Lymphoblastic Leukemia: Technological Advances, Clinical Translations and Current Challenges.Current issues in molecular biology · 2026Review
- Review
- Challenges and Advances in the Detection of Leukemic Blasts in Cerebrospinal Fluid in Pediatric Acute Lymphoblastic Leukemia.Cancers · 2026Review
- Artificial intelligence accelerates the interpretation of measurable residual B lymphoblastic leukemia by flow cytometry.Blood advances · 2026Article
- CAR-T versus allogeneic transplantation as consolidation for B-cell acute lymphoblastic leukemia in remission: a propensity-score matched study.Frontiers in immunology · 2026Article
131 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
26 authors at 10 institutions in 8 countries.
Prisca TheunissenDepartment of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Ester MejstrikovaChildhood Leukaemia Investigation Prague, Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, University Hospital Motol, Prague, Czech Republic.
Lukasz SedekDepartment of Pediatric Hematology and Oncology, Zabrze, Medical University of Silesia, Katowice, Poland.
Alita J van der Sluijs-GellingDutch Childhood Oncology Group, The Hague, The Netherlands.
Giuseppe GaipaCentro Ricerca Tettamanti, Clinica Pediatrica Università di Milano Bicocca, Monza, Italy.
Marius BartelsDepartment of Hematology, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Elaine Sobral da CostaDepartment of Pediatrics, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Michaela KotrováChildhood Leukaemia Investigation Prague, Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, University Hospital Motol, Prague, Czech Republic.
Michaela NovakovaChildhood Leukaemia Investigation Prague, Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, University Hospital Motol, Prague, Czech Republic.
Edwin SonneveldDutch Childhood Oncology Group, The Hague, The Netherlands.
Chiara BuracchiCentro Ricerca Tettamanti, Clinica Pediatrica Università di Milano Bicocca, Monza, Italy.
Paola BonaccorsoCentro Ricerca Tettamanti, Clinica Pediatrica Università di Milano Bicocca, Monza, Italy.
Elen OliveiraDepartment of Pediatrics, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Jeroen G Te MarveldeDepartment of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Tomasz SzczepanskiDepartment of Pediatric Hematology and Oncology, Zabrze, Medical University of Silesia, Katowice, Poland.
Ludovic LhermitteDepartment of Hematology, Hôpital Necker-Enfants-Malades and Unité Mixte de Recherche Centre National de la Recherche Scientifique 8147, University of Paris Descartes, Paris, France.
Ondrej HrusakChildhood Leukaemia Investigation Prague, Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, University Hospital Motol, Prague, Czech Republic.
Quentin LecrevisseCancer Research Center (Instituto de Biología Molecular y Celular del Cancer-Consejo Superior de Investigaciones Científicas), Department of Medicine and Cytometry Service, University of Salamanca, Institute of Biomedical Research of Salamanca, Salamanca, Spain; and.
Georgiana Emilia GrigoreCytognos SL, Salamanca, Spain.
Eva FroňkováChildhood Leukaemia Investigation Prague, Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, University Hospital Motol, Prague, Czech Republic.
Jan TrkaChildhood Leukaemia Investigation Prague, Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, University Hospital Motol, Prague, Czech Republic.
Monika BrüggemannDepartment of Hematology, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Alberto OrfaoCancer Research Center (Instituto de Biología Molecular y Celular del Cancer-Consejo Superior de Investigaciones Científicas), Department of Medicine and Cytometry Service, University of Salamanca, Institute of Biomedical Research of Salamanca, Salamanca, Spain; and.
Jacques J M van DongenDepartment of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Vincent H J van der VeldenDepartment of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
EuroFlow Consortium
Charles University · CZErasmus MC · NLKiel University · DEUniversity of Milano-Bicocca · ITMedical University of Silesia · PLStichting Kinderoncologie Nederland · NLUniversidade Federal do Rio de Janeiro · BRCentro de Investigación del Cáncer · ESConsejo Superior de Investigaciones Científicas · ESHôpital Necker-Enfants Malades · FR
Funding
No grant is acknowledged in the PubMed record.
Abstract
A fully-standardized EuroFlow 8-color antibody panel and laboratory procedure was stepwise designed to measure minimal residual disease (MRD) in B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) patients with a sensitivity of ≤10
Indexed as
AdolescentAdultAgedChildChild, PreschoolFemaleFlow CytometryGene RearrangementHumansInfantInfant, NewbornMaleMiddle AgedNeoplasm, ResidualPrecursor B-Cell Lymphoblastic Leukemia-LymphomaReal-Time Polymerase Chain ReactionReceptors, Antigen, B-Cell
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.